Merck Accelerates Vaccine & mRNA Cancer Innovation Amid Global Health Challenges
Merck pushes vaccine and mRNA innovation forward: Ervebo’s cross‑variant protection in DRC, a 15% relapse‑free gain in melanoma trials, and AI‑driven biotech partnerships.
4 minutes to read


